SuanNutra, a Carbyne Equity Partners company, has agreed to acquire a portfolio of speciality natural ingredients businesses from IFF.

The businesses will merge with SuanNutra’s existing operations to create a larger global player in natural ingredients. SuanNutra, based in Madrid, Spain, said the combination delivers directly on its strategy of scaling nutraceutical science into measurable impact and expanding into food-enhancement ingredients.

Expected to complete by the end of 2026, the transaction includes botanical extraction capabilities and fermented vitamins and minerals, plant-derived natural colours, antioxidants and flavour solutions. It includes operations that generated revenues of approximately $170 million in 2025.

The newly merged group will have around 700 employees, serving more than 1,200 customers in over 60 countries. Its combined manufacturing footprint spans botanical extraction in Spain, Slovenia and Peru, and fermentation in the US.

SuanNutra said existing customers will continue to be served without interruption, with the group continuing to invest in commercial capability, R&D and innovation.

Anthony Weston, group CEO of SuanNutra, said: “Together we will build, grow and transform this group into a stronger partner for our customers offering manufacturing at source, clinically proven ingredients and a broad natural portfolio across nutraceuticals and food enhancement”.

Yoni Glickman, non-executive chairman of SuanNutra, said that clinically supported, branded ingredients are “where this industry is heading,” adding: “The move from artificial colours and preservatives to natural, scientifically substantiated ingredients is reshaping the food and health industries faster than ever.”

Erik Fyrwald, CEO of IFF, commented: “These businesses are highly respected, and we are confident they will continue to thrive under the ownership of SuanNutra and Carbyne”.

“This transaction is another step in optimising our portfolio and reinforces our focus on our core innovation-led businesses – Taste, Scent and Health & Biosciences – where we see the greatest opportunities to drive long-term profitable growth and create value for our shareholders.”

Financial terms of the deal were not disclosed. The transaction is subject to customary closing conditions, including regulatory clearances.